{"protocolSection": {"identificationModule": {"nctId": "NCT00509028", "orgStudyIdInfo": {"id": "D5254C00006"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy Study of Budesonide (Pulmicort\u00ae) Turbuhaler\u00ae in Japanese Children With Bronchial Asthma", "officialTitle": "An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler\u00ae Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-12"}, "primaryCompletionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-07-17", "studyFirstSubmitQcDate": "2007-07-30", "studyFirstPostDateStruct": {"date": "2007-07-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-10-06", "resultsFirstSubmitQcDate": "2012-07-24", "resultsFirstPostDateStruct": {"date": "2012-08-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-24", "lastUpdatePostDateStruct": {"date": "2012-08-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres. To investigate the safety of budesonide Turbuhaler\u00ae with a daily dose of 100 \u00b5g to 800 \u00b5g for 54 weeks treatment including the prior 6 weeks Phase III study (Study D5254C00769, NCT00504062) as compared with conventional therapy in Japanese children with bronchial asthma in need of inhaled glucocorticosteroid treatment."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Bronchial"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 241, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BUD - Budesonide", "type": "EXPERIMENTAL", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily", "interventionNames": ["Drug: Budesonide"]}, {"label": "CONV - Conventional Asthma Therapy", "type": "ACTIVE_COMPARATOR", "description": "Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.", "interventionNames": ["Drug: Conventional Asthma Therapy"]}], "interventions": [{"type": "DRUG", "name": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily", "armGroupLabels": ["BUD - Budesonide"], "otherNames": ["Pulmicort\u00ae Turbuhaler\u00ae"]}, {"type": "DRUG", "name": "Conventional Asthma Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.", "armGroupLabels": ["CONV - Conventional Asthma Therapy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients With Adverse Events (AEs).", "description": "AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.", "timeFrame": "54 weeks"}], "secondaryOutcomes": [{"measure": "Number of Patients With Abnormal Clinical Laboratory Test Values.", "description": "Analysis of haematological, clinical chemistry and urynalysis variables were performed.\n\nHaematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.\n\nClinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.\n\nUrinalysis variables: protein, glucose, urobilinogen, occult.", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator", "timeFrame": "54 weeks"}, {"measure": "Number of Patients With Abnormal Plasma Cortisol Values.", "description": "Cut-off value of cortisol is defined as 4 mcg/dL.", "timeFrame": "54 weeks"}, {"measure": "Height", "description": "Height, change from baseline calculated as (height at last visit - height at randomization)", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Weight", "description": "Weight, change from baseline calculated as (weight at last visit - weight at randomization)", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal", "description": "Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).", "timeFrame": "54 weeks"}, {"measure": "Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)", "description": "Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.\n\n0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)", "description": "Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).\n\nScale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)", "description": "Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)", "description": "Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Change From Baseline in Disturbance of Daily Activities", "description": "Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).\n\nFrequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Change From Baseline in Disturbance of Night-time Sleep", "description": "Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).\n\nFrequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).", "timeFrame": "Baseline and 54 weeks"}, {"measure": "Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline", "description": "Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \\* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).", "timeFrame": "54 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient who complete preceding the Phase III study and provide a signed written informed consent by patient's legal representative at Visit 1 or 4 weeks prior to Visit 1 of the study. A signed written informed assent should also be obtained from the patients themselves as much as possible\n* When the investigator will obtain the signed written informed consent of Phase III study (D5254C00769) from patient's legal representative, the investigator will also provide the information of this study\n\nExclusion Criteria:\n\n* Respiratory infections that, in the opinion of the investigator(s), may affect the efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no available effective antimicrobial drugs or with deep seated mycosis\n* Concurrent serious diseases of liver, kidney, heart or other complications which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study. Any clinically relevant abnormal findings in vital sign or physical examination at Visit 1 in this study, which in the opinion of the investigator may put the patient at risk because of his/her participation in the study.\n* Pregnant or possible pregnancy or planning to become pregnant during the study period\n* Other subjects who are considered inappropriate to participate in this study judged by the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "15 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lars-Goran Carlsson, MD", "affiliation": "AstraZeneca R&D Lund", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Takizawa", "state": "Iwate", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This was an open-label, multi-centre, long-term study in Japanese children with bronchial asthma aged 5 to 15 years, and conducted as an extension of the Phase III study D5254C00769.", "recruitmentDetails": "241 Japanese paediatric patients were enrolled into the study", "groups": [{"id": "FG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "FG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "121"}, {"groupId": "FG001", "numSubjects": "120"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "109"}, {"groupId": "FG001", "numSubjects": "113"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "BG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "121"}, {"groupId": "BG001", "value": "120"}, {"groupId": "BG002", "value": "241"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.9", "spread": "2.6"}, {"groupId": "BG001", "value": "8.6", "spread": "2.3"}, {"groupId": "BG002", "value": "8.8", "spread": "2.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "63"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "93"}, {"groupId": "BG002", "value": "178"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients With Adverse Events (AEs).", "description": "AEs were defined as undesirable medical conditions or deteriorations of a pre-existing medical condition following/during exposure. All Serious AEs, AEs leading to withdrawal, Other relevant AE were recorded.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "116"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Abnormal Clinical Laboratory Test Values.", "description": "Analysis of haematological, clinical chemistry and urynalysis variables were performed.\n\nHaematology variables: erythrocytes, haemoglobin, haematocrit, leucocyte count, leucocyte different count (neutrophils, eosinophils, basophils, lymphocytes, monocytes), platelet count.\n\nClinical chemistry measurements: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, albumin, creatinine,sodium, potassium, total protein, blood urea nitrogen.\n\nUrinalysis variables: protein, glucose, urobilinogen, occult.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Abnormal Plasma Cortisol Values.", "description": "Cut-off value of cortisol is defined as 4 mcg/dL.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Height", "description": "Height, change from baseline calculated as (height at last visit - height at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Centimeters", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.34", "spread": "1.99"}, {"groupId": "OG001", "value": "6.35", "spread": "1.89"}]}]}]}, {"type": "SECONDARY", "title": "Weight", "description": "Weight, change from baseline calculated as (weight at last visit - weight at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kilograms", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "113"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.78", "spread": "2.77"}, {"groupId": "OG001", "value": "4.39", "spread": "3.22"}]}]}]}, {"type": "SECONDARY", "title": "Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal", "description": "Change in PEF percent of predicted normal calculated as (PEF percent predicted normal at last visit - PEF percent predicted normal at randomization).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.54", "spread": "19.87"}, {"groupId": "OG001", "value": "5.84", "spread": "17.81"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)", "description": "Change in respiratory condition at asthma attacks (daytime) from baseline to last visit. Scale: 0 - 4.\n\n0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Points on a scale", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.139", "spread": "0.334"}, {"groupId": "OG001", "value": "-0.156", "spread": "0.302"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)", "description": "Change in respiratory condition at asthma attacks (nighttime) from baseline calculated as (respiratory condition at asthma attacks (nighttime) at last visit - respiratory condition at asthma attacks (night-time) at randomization).\n\nScale: 0 - 4. 0 = None. 1 = Mild. 2 = Moderate. 3= Severe. 4 = Respiratory insufficiency.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Points on a scale", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "0.29"}, {"groupId": "OG001", "value": "-0.147", "spread": "0.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)", "description": "Change in use of inhaled short-acting B-2 agonist (daytime) from baseline calculated as (use of inhaled short-acting B-2 agonist (daytime) at last visit - use of inhaled short-acting B-2 agonist (daytime) at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs per day", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.647"}, {"groupId": "OG001", "value": "-0.242", "spread": "0.485"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)", "description": "Change in use of inhaled short-acting B-2 agonist (night-time) from baseline calculated as (use of inhaled short-acting B-2 agonist (night-time) at last visit - use of inhaled short-acting B-2 agonist (night-time) at randomization)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs per day", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.415"}, {"groupId": "OG001", "value": "-0.097", "spread": "0.368"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Disturbance of Daily Activities", "description": "Change in disturbance of daily activities from baseline calculated as (disturbance of daily activities at last visit - disturbance of daily activities at randomization).\n\nFrequency of disturbance of daily activity was assessed using 3- grade scale (normal, almost able, unable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Disturbances per day", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.037", "spread": "0.141"}, {"groupId": "OG001", "value": "-0.017", "spread": "0.141"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Disturbance of Night-time Sleep", "description": "Change in disturbance of night-time sleep from baseline calculated as (disturbances of night-time sleep at last visit - disturbances of night-time sleep at randomization).\n\nFrequency of disturbance of night- time sleep was assessed using 3- grade scale (normal, almost able, unable).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Disturbances per night", "timeFrame": "Baseline and 54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.029", "spread": "0.134"}, {"groupId": "OG001", "value": "-0.042", "spread": "0.132"}]}]}]}, {"type": "SECONDARY", "title": "Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline", "description": "Forced Expiratory Volume in one second (FEV1) percentage of predicted normal change from baseline calculated as: 100 \\* (FEV1 at last visit - FEV1 at randomization)/predicted normal FEV1).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily."}, {"id": "OG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "15.59"}, {"groupId": "OG001", "value": "2.31", "spread": "16.63"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Budesonide", "description": "Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily.", "seriousNumAffected": 10, "seriousNumAtRisk": 121, "otherNumAffected": 100, "otherNumAtRisk": 121}, {"id": "EG001", "title": "Conventional Therapy", "description": "According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.", "seriousNumAffected": 11, "seriousNumAtRisk": 120, "otherNumAffected": 113, "otherNumAtRisk": 120}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}]}, {"term": "Adenoviral conjunctivitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 120}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Enterocolitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 120}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 120}]}, {"term": "Gastroenteritis rotavirus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 120}]}], "otherEvents": [{"term": "Conjunctivitis Allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 120}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 68, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 60, "numAtRisk": 120}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 40, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 46, "numAtRisk": 120}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 40, "numAtRisk": 120}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 120}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 120}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 120}]}, {"term": "Otitis Media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 120}]}, {"term": "Chronic Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 120}]}, {"term": "Acute Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 120}]}, {"term": "Impetigo", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 120}]}, {"term": "Hordeolum", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 120}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 120}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 120}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 120}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 120}]}, {"term": "Dermatitis Atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}]}, {"term": "Dry Skin", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}]}, {"term": "Heat Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 121}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 120}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "AZTrial_Results_Posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}